Jakson kuvaus
Moderna's melanoma trial results moved the stock this week — and a lot of the healthcare sector with it. The excitement is real. Personalized, tumor-built cancer treatment is a genuine medical leap. But here's the number that should temper the "this fixes healthcare spending" take: cancer treatment is only 6.7% of U.S. healthcare spend. Cure it completely, and the number that actually matters — the 20% of GDP we're on pace to hit by 2030 — barely moves. This edition of The Weekly Insight cove...

